Can Fite Biofarma (XTAE:CANF) 3-Year Revenue Growth Rate : -37.00% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma 3-Year Revenue Growth Rate?

Can Fite Biofarma's Revenue per Share for the three months ended in Dec. 2023 was ₪0.00.

During the past 12 months, Can Fite Biofarma's average Revenue per Share Growth Rate was -50.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -37.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -64.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Can Fite Biofarma was 137.70% per year. The lowest was -74.80% per year. And the median was -46.45% per year.

Competitive Comparison of Can Fite Biofarma's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Can Fite Biofarma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's 3-Year Revenue Growth Rate falls into.

Can Fite Biofarma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Can Fite Biofarma (XTAE:CANF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Can Fite Biofarma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (XTAE:CANF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

CANF:USA

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).